Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Catatonia and neuroleptic malignant syndrome

Psychiatry · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Fever and rigidity are a medical emergency

Catatonic signs with hyperthermia, autonomic instability or reduced consciousness may represent malignant catatonia or neuroleptic malignant syndrome and can progress to organ failure.

Action: Call senior medical, psychiatric and critical-care support, stop dopamine antagonists when NMS or malignant catatonia is suspected, stabilise ABCDE and investigate renal injury, electrolyte disturbance and alternative causes without delaying treatment.

Overview

Identify a catatonic motor syndrome and dopamine-blocker-associated systemic toxicity, initiate urgent supportive care and distinguish their treatment priorities from ordinary psychotic agitation.

Catatonia is often recognised too late because reduced movement is interpreted as refusal, depression or the negative symptoms of schizophrenia. The syndrome is defined through a combination of observable signs. Mutism, stupor and withdrawal are important but nonspecific; posturing, catalepsy, negativism, stereotyped behaviour and echolalia or echopraxia provide additional clues. The BAP guideline recommends diagnosis based on at least three catatonic signs. Excited catatonia can involve purposeless overactivity rather than immobility.

Examine respectfully and explain what you are doing. A person who does not speak or move may still hear and remember events. Observe spontaneous behaviour, responses to instructions and changes with examination, using an instrument such as the Bush–Francis Catatonia Rating Scale to support a reproducible record. Establish the baseline, including autistic traits or longstanding movement abnormalities, and ask about previous episodes, mood symptoms, psychosis, medicines, substance withdrawal and neurological illness.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Rigidity after dopamine blockade

A patient develops fever, diffuse rigidity, confusion and unstable blood pressure after an antipsychotic dose increase. CK is elevated and renal function is worsening. What is the immediate treatment priority?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status3 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • BAP evidence-based catatonia consensus guideline 2023Diagnosis, challenge dosing, malignant catatonia, NMS and recurrence prevention.
  • NICE TA59 guidance on electroconvulsive therapyECT for severe catatonia with consent and safety considerations.
  • Haloperidol injection UK SmPC NMS warningsRecognition and withdrawal of treatment when NMS is suspected.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Catatonia is not an aetiological diagnosis. Consider severe depression or mania, psychotic illness, encephalitis, seizure disorders, metabolic abnormalities, neurological disease and medication effects. New or atypical catatonia may require neurological investigations, including EEG or autoimmune encephalitis assessment when features support them. Delirium and catatonic signs can coexist in medically ill patients, making joint assessment particularly valuable. Treatment should not wait for every investigation when complications are developing.

NMS is a severe drug-related syndrome most often associated with dopamine antagonists, including antipsychotics and some antiemetics. Recent initiation, dose escalation or parenteral treatment may precede it, but absence of a classic exposure change does not exclude the diagnosis. Fever, marked rigidity, altered consciousness and autonomic instability are characteristic; raised creatine kinase supports muscle injury but is not a diagnostic test by itself. Restraint, seizures and other causes can also raise CK.

Malignant catatonia and NMS overlap clinically. A preceding catatonic syndrome and the medication timeline can help, but the first priorities are similar: recognise danger, stop dopamine antagonists, provide intensive supportive care and involve specialists. Prevent aspiration, dehydration, renal injury, thromboembolism and pressure damage. Specific treatment depends on the syndrome and severity. After recovery, ongoing management must address the underlying illness and avoid abrupt benzodiazepine withdrawal or premature antipsychotic rechallenge.

Key points

  • Catatonia is a syndrome of altered motor activity, speech and behaviour that occurs in mood, psychotic, neurological and general medical conditions.
  • Look for combinations of stupor, mutism, posturing, negativism, catalepsy, stereotypy and echo phenomena rather than immobility alone.
  • Use a structured catatonia examination and severity scale to document findings and change over time.
  • A monitored lorazepam challenge can support diagnosis, but improvement is not completely specific and lack of response does not exclude catatonia.
  • NMS is associated with dopamine-blocking exposure and usually features rigidity, fever, altered mental state and autonomic disturbance.
  • Stop implicated drugs and provide active medical support; do not respond to suspected NMS by escalating antipsychotics.
  • Benzodiazepines and ECT have central roles in catatonia, with urgent specialist escalation for malignant or poorly responsive illness.

Aetiology

01

Psychiatric and neurological associations

Catatonia may accompany mood or psychotic illness, encephalitis, epilepsy and other medical disorders, so recognition of the motor syndrome must lead to a cause assessment.

02

Dopamine-blocking exposure

Antipsychotics and dopamine-blocking antiemetics can precipitate NMS, with dehydration, acute illness and treatment changes adding clinically relevant vulnerability.

Pathophysiology

  1. 1
    Motor-network dysregulation

    Catatonia involves disturbed initiation and regulation of movement, speech and behaviour, with implicated GABAergic and other neural systems rather than one proven universal mechanism.

  2. 2
    Dopaminergic disruption

    Dopamine antagonism contributes to the rigidity and autonomic features of NMS, while overlapping catatonic phenomena make a purely mechanistic bedside distinction difficult.

  3. 3
    Systemic consequences

    Sustained muscle activity or rigidity, poor intake and autonomic instability can produce hyperthermia, dehydration, muscle breakdown and secondary renal or circulatory dysfunction.

Clinical features and red flags

Characteristic motor signs

Posturing, catalepsy, waxy flexibility, negativism and repetitive or echo behaviours become more informative when several occur together.

Loss of basic intake

Reduced eating, drinking or swallowing can create immediate medical risk even when observations and temperature initially appear reassuring.

Malignant progression

Fever, tachycardia, unstable blood pressure, diaphoresis and worsening consciousness suggest systemic involvement requiring urgent medical escalation.

Drug-related rigidity

A dopamine-blocker exposure followed by diffuse rigidity, confusion and fever should prompt NMS assessment, including medicines given for nausea.

Red flags requiring action

  • Mutism or immobility with inability to eat or drink needs urgent assessment for dehydration, aspiration, thrombosis and an underlying neurological or psychiatric disorder.
  • Fever, generalised rigidity, tachycardia or blood-pressure instability after an antipsychotic or dopamine-blocking antiemetic requires immediate consideration of NMS.

Investigations

  1. 01
    Structured motor and behavioural examinationFirst step
    Why
    Document the number, nature and severity of catatonic signs before and during treatment.
    Interpretation and limitations
    A rating scale helps track response but does not establish the underlying cause; baseline neurodevelopmental features and communication barriers need consideration.
  2. 02
    Physiology, hydration and complication assessment
    Why
    Identify fever, circulatory instability, aspiration, pressure injury and consequences of poor intake or immobility.
    Interpretation and limitations
    Clinical severity determines the need for acute medical or intensive care even when the definitive syndrome remains uncertain.
  3. 03
    CK, renal profile, electrolytes and other targeted blood tests
    Why
    Assess muscle injury, renal risk, metabolic contributors and suspected infection or organ dysfunction.
    Interpretation and limitations
    Raised CK is supportive of muscle injury and may guide monitoring, but neither its presence nor absence alone confirms or excludes NMS.
  4. 04
    Medication and withdrawal timeline
    Why
    Identify dopamine antagonists, abrupt benzodiazepine withdrawal and other treatment-related triggers.
    Interpretation and limitations
    Check administration records, depot dates and antiemetics; a prescription list may miss a single recent injection or doses actually omitted.
  5. 05
    EEG, neuroimaging and encephalitis investigations
    Why
    Investigate neurological causes when the history, examination or first presentation warrants them.
    Interpretation and limitations
    Non-convulsive seizures and encephalitis can resemble catatonia; choose investigations with neurology rather than attributing new motor signs automatically to mental illness.

Differential diagnosis

01

Non-convulsive status epilepticus

Reduced responsiveness and abnormal behaviour can reflect ongoing seizure activity, particularly with epilepsy or neurological illness, making EEG important when suspicion exists.

02

Serotonin toxicity

A serotonergic exposure with clonus and hyperreflexia may distinguish this syndrome from the more rigid hypokinetic pattern of NMS, although mixed presentations occur.

03

Delirium or encephalitis

Acute cognitive change, fever and behavioural disturbance can arise from medical brain dysfunction and may coexist with catatonic signs requiring combined investigation.

Management

01Suspected catatoniaConfirm signs and protect basic careFirst stepSeveral catatonic motor or behavioural features are present without immediate malignant instability.+
  1. 1Record a structured baseline examination and assess hydration, nutrition, swallowing, mobility and pressure or thrombosis risks.
  2. 2Obtain urgent psychiatric input while investigating the underlying cause, including neurological assessment when the presentation is new or atypical.
  3. 3Consider a monitored lorazepam challenge and arrange continuing benzodiazepine or ECT treatment according to response, severity and individual risk.
02NMS or malignant catatoniaTreat systemic deterioration immediatelyCatatonic or rigid features occur with fever, autonomic instability, altered consciousness or evolving organ injury.+
  1. 1Stop dopamine antagonists and assess other implicated medicines, urgently involving acute medicine, psychiatry and critical care.
  2. 2Provide airway and circulatory support, temperature management, fluid and electrolyte treatment and active prevention of aspiration, thrombosis and renal injury.
  3. 3Arrange syndrome-specific specialist treatment; malignant catatonia with partial or absent lorazepam response within forty-eight to seventy-two hours requires urgent ECT consideration under the BAP pathway.
03Recovery phasePrevent withdrawal and recurrenceMotor signs and physiological complications are improving and long-term treatment decisions are required.+
  1. 1Treat the underlying mood, psychotic, neurological or medical disorder and continue functional, nutritional and complication assessment during recovery.
  2. 2Taper benzodiazepines through an individual plan rather than stopping abruptly, reviewing recurrence of catatonia if symptoms return.
  3. 3After NMS, delay antipsychotic reintroduction for at least two weeks after resolution and arrange cautious specialist selection, low-dose titration and close monitoring.
Key medicines and prescribing safety2 treatments · regimens, roles and cautions+
An off-label diagnostic and therapeutic trial that may rapidly reduce catatonic signs and inform ongoing specialist treatment.

Lorazepam challenge for catatonia

BAP describes a single challenge of 1–2 mg intravenously or intramuscularly, or 2 mg orally, after documenting baseline catatonic signs. Reassess after approximately 5 minutes for intravenous, 15 minutes for intramuscular and 30 minutes for oral administration; consider a further challenge only after clinical review.

Use a monitored setting with assessment of respiratory reserve, sedative co-exposure and aspiration risk. A substantial score reduction supports catatonia but is not completely specific; absence of improvement does not rule it out.

Off-label treatment of a life-threatening catatonic syndrome while supportive care and urgent ECT planning proceed.

Continuing lorazepam in malignant catatonia

The BAP specialist recommendation is 8 mg daily by oral, intramuscular or intravenous routes, divided and titrated to response and tolerability, up to 24 mg daily when required. Partial or absent response within forty-eight to seventy-two hours prompts bilateral ECT; titration and taper require direct specialist supervision.

These are specialist high-dose regimens, not routine agitation prescriptions; respiratory disease, frailty, concurrent depressants and sedation may limit dosing. Monitor closely and do not delay ECT or critical-care escalation when deterioration continues.

Complications

01

Aspiration and malnutrition

Impaired intake, swallowing and mobility expose patients to dehydration, nutritional depletion and aspiration, sometimes before dramatic autonomic abnormalities emerge.

02

Rhabdomyolysis and renal injury

Hyperthermia and severe muscle disturbance may release myoglobin and disturb electrolytes, threatening kidney function and cardiac stability without prompt supportive treatment.

03

Immobility-related injury

Prolonged reduced movement increases pressure damage, contracture and thromboembolism risk, requiring preventive nursing and medical care alongside syndrome-specific treatment.

Monitoring and follow-up

  • Track the same catatonic signs before and after treatment while also recording eating, drinking, movement, communication and ability to participate in care.
  • Repeat temperature, cardiorespiratory observations, hydration and renal or muscle-injury investigations at a frequency matched to severity and trends.
  • Assess swallowing, aspiration, venous thromboembolism risk, skin integrity and nutrition daily during immobility, using appropriate preventive interventions.
  • Observe respiratory state and consciousness during benzodiazepine treatment, particularly with high doses, lung disease or other sedative medicines.
  • Document NMS prominently, review future dopamine-blocking prescriptions and provide the patient and carers with early recurrence signs and a clear specialist plan.

Special situations

Mutism is not refusal

The inability to initiate speech or movement can be part of a treatable syndrome, and staff should continue respectful explanation and supportive care.

A challenge is not absolute

Lorazepam can improve conditions other than catatonia, while some catatonic patients respond incompletely, so the examination and wider context remain important.

CK has several causes

Muscle exertion, seizures and intramuscular injections can elevate creatine kinase, making a laboratory-only diagnosis of NMS unreliable.

ECT may be urgent

Severe catatonia can threaten life through autonomic instability or failure of intake, so consent and legal arrangements should be addressed early alongside physical preparation.

Common pitfalls

  1. 01

    Calling immobility or mutism deliberate non-cooperation without examining for catatonic motor signs and assessing basic physical needs.

  2. 02

    Treating suspected malignant catatonia or NMS with additional antipsychotics because agitation or psychosis is also present.

  3. 03

    Waiting for a very high CK concentration before escalating a clinically deteriorating patient.

  4. 04

    Using a negative lorazepam challenge as the sole reason to exclude catatonia or stop investigating neurological mimics.

  5. 05

    Restarting antipsychotics immediately after fever settles or abruptly withdrawing benzodiazepines after an initial response.